Recent advances in understanding/managing eosinophilic esophagitis in adults
It is an exciting time for research in eosinophilic esophagitis (EoE). As a new and increasingly prevalent disease, it is receiving considerable attention in the medical world, resulting in a flood of new insights. Clearly, a genetic predisposition seems likely with the identification of abnormaliti...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
F1000Research
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544371/ |
| id |
pubmed-4544371 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-45443712015-09-02 Recent advances in understanding/managing eosinophilic esophagitis in adults Katzka, David A. Review It is an exciting time for research in eosinophilic esophagitis (EoE). As a new and increasingly prevalent disease, it is receiving considerable attention in the medical world, resulting in a flood of new insights. Clearly, a genetic predisposition seems likely with the identification of abnormalities in thymic stromal lymphopoietin (TSLP), calpain14, and eotaxin-3 genes. There are also well-defined abnormalities described in esophageal epithelial barrier function in these patients. The relationship between gastroesophageal reflux disease (GERD) and EoE remains unclear, but emerging data suggest that the concept of proton pump inhibitor responsive esophageal eosinophilia (PPIREE) may retain less importance, as this subset of patients becomes a likely subset of EoE in general. Finally, we approach the looming issue of long-term maintenance therapy. Although we lack adequate specific data on how to provide long-term pharmacologic treatment, studies clearly show that for most patients, this is a progressive disease that warrants such consideration. F1000Research 2015-08-20 /pmc/articles/PMC4544371/ /pubmed/26339483 http://dx.doi.org/10.12688/f1000research.6942.1 Text en Copyright: © 2015 Katzka DA http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Katzka, David A. |
| spellingShingle |
Katzka, David A. Recent advances in understanding/managing eosinophilic esophagitis in adults |
| author_facet |
Katzka, David A. |
| author_sort |
Katzka, David A. |
| title |
Recent advances in understanding/managing eosinophilic esophagitis in adults |
| title_short |
Recent advances in understanding/managing eosinophilic esophagitis in adults |
| title_full |
Recent advances in understanding/managing eosinophilic esophagitis in adults |
| title_fullStr |
Recent advances in understanding/managing eosinophilic esophagitis in adults |
| title_full_unstemmed |
Recent advances in understanding/managing eosinophilic esophagitis in adults |
| title_sort |
recent advances in understanding/managing eosinophilic esophagitis in adults |
| description |
It is an exciting time for research in eosinophilic esophagitis (EoE). As a new and increasingly prevalent disease, it is receiving considerable attention in the medical world, resulting in a flood of new insights. Clearly, a genetic predisposition seems likely with the identification of abnormalities in thymic stromal lymphopoietin (TSLP), calpain14, and eotaxin-3 genes. There are also well-defined abnormalities described in esophageal epithelial barrier function in these patients. The relationship between gastroesophageal reflux disease (GERD) and EoE remains unclear, but emerging data suggest that the concept of proton pump inhibitor responsive esophageal eosinophilia (PPIREE) may retain less importance, as this subset of patients becomes a likely subset of EoE in general. Finally, we approach the looming issue of long-term maintenance therapy. Although we lack adequate specific data on how to provide long-term pharmacologic treatment, studies clearly show that for most patients, this is a progressive disease that warrants such consideration. |
| publisher |
F1000Research |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544371/ |
| _version_ |
1613262025096429568 |